Jeffrey Rubnitz - Senior Medical ...

Dr. Jeffrey E. Rubnitz, MD, PhD

Claim this profile

St. Jude Children's Research Hospital

Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
13 reported clinical trials
25 drugs studied

Area of expertise

1

Acute Myelogenous Leukemia

Jeffrey E. Rubnitz, MD, PhD has run 10 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:

t(9;11) positive
inv(16) positive
t(8;21) positive
2

Acute Myeloid Leukemia

Jeffrey E. Rubnitz, MD, PhD has run 9 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

t(9;11) positive
inv(16) positive
t(8;21) positive

Affiliated Hospitals

Image of trial facility.

St Jude Children's Research Hospital

Image of trial facility.

Saint Jude Children's Research Hospital

Clinical Trials Jeffrey E. Rubnitz, MD, PhD is currently running

Image of trial facility.

Talazoparib + Chemotherapy

for Acute Myeloid Leukemia

This trial is testing the safety of using talazoparib with standard chemotherapy in cancer patients. Talazoparib works by stopping cancer cells from repairing themselves, which could make chemotherapy more effective. The study aims to find the safest dose combination and see if this approach helps patients. Talazoparib is FDA approved for certain types of breast cancer that have spread and were previously treated with chemotherapy.

Recruiting

1 award

Phase 1

19 criteria

Image of trial facility.

Revumenib + Chemotherapy

for Acute Myeloid Leukemia

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in participants also taking an anti-fungal drug. Primary Objective * To determine the safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives * Describe the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and overall survival for patients treated with revumenib + azacitidine + venetoclax at the recommended phase 2 dose (RP2D).

Recruiting

1 award

Phase 1

10 criteria

More about Jeffrey E. Rubnitz, MD, PhD

Clinical Trial Related

6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Jeffrey E. Rubnitz, MD, PhD has experience with

  • Cytarabine
  • Venetoclax
  • Azacitidine
  • Fludarabine
  • Decitabine
  • Selinexor

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jeffrey E. Rubnitz, MD, PhD specialize in?

Is Jeffrey E. Rubnitz, MD, PhD currently recruiting for clinical trials?

Are there any treatments that Jeffrey E. Rubnitz, MD, PhD has studied deeply?

What is the best way to schedule an appointment with Jeffrey E. Rubnitz, MD, PhD?

What is the office address of Jeffrey E. Rubnitz, MD, PhD?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security